ATE410179T1 - Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern - Google Patents

Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern

Info

Publication number
ATE410179T1
ATE410179T1 AT04022921T AT04022921T ATE410179T1 AT E410179 T1 ATE410179 T1 AT E410179T1 AT 04022921 T AT04022921 T AT 04022921T AT 04022921 T AT04022921 T AT 04022921T AT E410179 T1 ATE410179 T1 AT E410179T1
Authority
AT
Austria
Prior art keywords
beta
alpha
treatment
liver fibrosis
integrin antibodies
Prior art date
Application number
AT04022921T
Other languages
English (en)
Inventor
Xiaozhu Huang
Dean Sheppard
Robert Pytela
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE410179T1 publication Critical patent/ATE410179T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04022921T 1997-08-08 1998-08-07 Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern ATE410179T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
ATE410179T1 true ATE410179T1 (de) 2008-10-15

Family

ID=21995323

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04022921T ATE410179T1 (de) 1997-08-08 1998-08-07 Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern
AT98939278T ATE286742T1 (de) 1997-08-08 1998-08-07 Behandlung von nierenfibrose durch antikörper gegen integrin alpha-v-beta 6
AT08004714T ATE511850T1 (de) 1997-08-08 1998-08-07 Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT98939278T ATE286742T1 (de) 1997-08-08 1998-08-07 Behandlung von nierenfibrose durch antikörper gegen integrin alpha-v-beta 6
AT08004714T ATE511850T1 (de) 1997-08-08 1998-08-07 Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin

Country Status (23)

Country Link
US (5) US20020004482A1 (de)
EP (3) EP1504764B1 (de)
JP (2) JP2001513333A (de)
KR (1) KR100586202B1 (de)
CN (1) CN1267224A (de)
AT (3) ATE410179T1 (de)
AU (1) AU739283B2 (de)
BR (1) BR9814040A (de)
CA (1) CA2297736A1 (de)
CY (2) CY1110462T1 (de)
CZ (1) CZ299768B6 (de)
DE (2) DE69828614T2 (de)
DK (2) DK1930022T3 (de)
EE (1) EE04752B1 (de)
ES (3) ES2311131T3 (de)
HU (1) HU228900B1 (de)
IL (2) IL134288A0 (de)
NZ (2) NZ502546A (de)
PL (2) PL199014B1 (de)
PT (3) PT996460E (de)
RU (1) RU2221589C2 (de)
TR (2) TR200000374T2 (de)
WO (1) WO1999007405A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
ATE410179T1 (de) * 1997-08-08 2008-10-15 Univ California Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern
CN100360183C (zh) * 1999-04-22 2008-01-09 比奥根艾迪克Ma公司 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物中的用途
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
EP1492870A4 (de) * 2002-04-12 2005-08-03 Raven Biotechnologies Inc An integrin-alpha-v-beta-6 bindende antikörper sowie verfahren zur verwendung davon
EP2394662B1 (de) * 2004-04-02 2018-03-21 The Regents of The University of California Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha v beta 5-integrin assoziierten krankheiten
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
BRPI0714381A2 (pt) 2006-07-10 2013-03-05 Biogen Idec Inc composiÇÕes e mÉtodos para inibir crescimento de cÂnceres deficientes em smad4
JP5362563B2 (ja) 2006-08-03 2013-12-11 アストラゼネカ・アクチエボラーグ αＶβ６に対する抗体およびその使用
EP2087008A1 (de) * 2006-10-19 2009-08-12 The Regents of the University of California BEHANDLUNG UND PRÄVENTION VON CHRONISCHEM ASTHMA MIT INTEGRIN-alphaVbeta6-ANTAGONISTEN
EP2185198B1 (de) * 2007-08-02 2015-01-14 Gilead Biologics, Inc. Lox- und loxl2-hemmer und verwendungen davon
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
KR20120063488A (ko) 2009-08-21 2012-06-15 길리아드 바이오로직스, 인크. 리실 옥시다제 및 ｌｏｘｌ２로부터의 촉매 도메인
AU2010283997B2 (en) * 2009-08-21 2015-04-09 Gilead Biologics, Inc. Methods and compositions for treatment of pulmonary fibrotic disorders
RU2015108348A (ru) * 2010-02-04 2015-07-20 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
SG11201404354UA (en) 2012-02-17 2014-10-30 Seattle Genetics Inc ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EP2784511A1 (de) 2013-03-27 2014-10-01 Universität Zürich Integrin-alpha-v-beta 6 zur Diagnose/Prognose von Kolorektalkarzinomen
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
US20190144547A1 (en) * 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
JP2020531521A (ja) 2017-08-22 2020-11-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファ（ｖ）ベータ（６）抗体を含有する医薬組成物及び投薬計画
JP7551750B2 (ja) 2019-12-05 2024-09-17 シージェン インコーポレイテッド 抗αｖβ６抗体及び抗体薬物コンジュゲート
MX2022013753A (es) * 2020-05-07 2023-01-30 Pliant Therapeutics Inc Tratamiento de enfermedades respiratorias con compuestos de aminoacidos.
CN120960406A (zh) * 2024-05-16 2025-11-18 浙江大学 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
FI912858A0 (fi) 1988-12-20 1991-06-13 Jolla Cancer Res Found Polypeptidpolymerkonjugat aktiva vid botande av saor.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
EP0719859B1 (de) * 1994-12-20 2003-07-02 MERCK PATENT GmbH Monoklonaler Antikörper gegen das Alpha-V-Integrin
ATE410179T1 (de) * 1997-08-08 2008-10-15 Univ California Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern

Also Published As

Publication number Publication date
HU228900B1 (en) 2013-06-28
PT1504764E (pt) 2009-01-14
AU8774398A (en) 1999-03-01
EP0996460A1 (de) 2000-05-03
CA2297736A1 (en) 1999-02-18
KR20010022740A (ko) 2001-03-26
ES2235350T3 (es) 2005-07-01
US7150871B2 (en) 2006-12-19
CZ299768B6 (cs) 2008-11-19
EP0996460B1 (de) 2005-01-12
EE200000068A (et) 2000-10-16
EP1930022B1 (de) 2011-06-08
EP1930022A1 (de) 2008-06-11
PL341029A1 (en) 2001-03-26
JP2009001587A (ja) 2009-01-08
US6692741B2 (en) 2004-02-17
NZ515955A (en) 2003-04-29
PL199014B1 (pl) 2008-08-29
KR100586202B1 (ko) 2006-06-07
EE04752B1 (et) 2006-12-15
AU739283B2 (en) 2001-10-11
ES2311131T3 (es) 2009-02-01
TR200000374T2 (tr) 2000-09-21
CN1267224A (zh) 2000-09-20
DE69840113D1 (de) 2008-11-20
DK1504764T3 (da) 2008-11-17
PL201716B1 (pl) 2009-05-29
NZ502546A (en) 2002-02-01
CZ2000413A3 (cs) 2000-11-15
BR9814040A (pt) 2000-10-03
WO1999007405A1 (en) 1999-02-18
RU2221589C2 (ru) 2004-01-20
EP1504764A1 (de) 2005-02-09
HUP0003547A2 (hu) 2001-02-28
DE69828614D1 (de) 2005-02-17
ATE286742T1 (de) 2005-01-15
US20070148173A1 (en) 2007-06-28
ATE511850T1 (de) 2011-06-15
US6316601B1 (en) 2001-11-13
US20040208878A1 (en) 2004-10-21
CY1110462T1 (el) 2015-04-29
DE69828614T2 (de) 2006-02-09
CY1111792T1 (el) 2015-10-07
US20020004482A1 (en) 2002-01-10
IL134288A0 (en) 2001-04-30
ES2364703T3 (es) 2011-09-12
PT996460E (pt) 2005-04-29
US7544358B2 (en) 2009-06-09
TR200202323T2 (tr) 2002-12-23
EP1504764B1 (de) 2008-10-08
US20010056076A1 (en) 2001-12-27
IL134288A (en) 2008-07-08
EP0996460A4 (de) 2001-03-07
HUP0003547A3 (en) 2002-05-28
DK1930022T3 (da) 2011-07-25
PT1930022E (pt) 2011-08-01
JP2001513333A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
ATE410179T1 (de) Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern
EP0730609A4 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
SI1007089T1 (sl) Antikoagulantska humanizirana protitelesa proti faktorju IX za uporabo pri zdravljenju tromboze
CY2009018I2 (el) Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη
DE69327891D1 (de) Material zur Entfernung von pathogener Substanz und mit diesem Material hergestellter Blutfilter
IL117993A0 (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
DE68912302D1 (de) Härtendes material für medizinischen und dentalen gebrauch.
DE69529414D1 (de) Intraluminarer katheter mit hochfesten proximalen schaft
ATE441667T1 (de) Antikírper für die behandlung von einer immunerkrankung
FI963101L (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
NZ288883A (en) Conjugates comprising coagulation factors
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
FI830573A7 (fi) Syövän diagnoosissa ja hoidossa hyödylliset vasta-aineet ja antigeenit.
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
ATE114974T1 (de) Abgabe von cytotoxischen mitteln.
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
EP1013642A3 (de) Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
DE69113811D1 (de) Zusammensetzung zur lokalen anwendung.
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
DE69017825D1 (de) Heilverfahren von Lebererkrankungen mit Verwendung von Pyrrol-Chinolin-Chinone-Triester und neue Pyrrol-Chinolin-Chinone-Triester.
EE9700021A (et) Fibriinile mõju avaldav monoklooniline antikeha kasutamiseks tromboosivastases ravis, farmatseutilised kompositsioonid ja ravimaine
RU99123884A (ru) Способ лечения параноидной шизофрении
PT741746E (pt) Compostos sinteticos relacionados com a timosina alfa1 e novos metodos para a sua sintese
DE60014358D1 (de) Verwendung von org 33245 in der kombinierten intermittierenden hormontherapie und empfängnisverhütung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1504764

Country of ref document: EP